PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35324532-10	2022	In addition, the apparent lack of response to selpercatinib plus crizotinib in this case highlights the need for future cohort studies for examining the value of combining RET and MET inhibitors in treating RET-rearranged, MET-amplified NSCLC.	Crizotinib	65-75	ret proto-oncogene	Homo sapiens	172-175	
34957368-12	2021	Moreover, RET-CCDC6 fusion and EGFR mutation were detected following crizotinib treatment in two patients, suggesting novel mechanisms of resistance.	Crizotinib	69-79	ret proto-oncogene	Homo sapiens	10-13	
32778510-0	2021	A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.	Crizotinib	107-117	ret proto-oncogene	Homo sapiens	34-37	
33082208-0	2021	Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib.	Crizotinib	145-155	ret proto-oncogene	Homo sapiens	49-52	
33082208-0	2021	Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib.	Crizotinib	145-155	ret proto-oncogene	Homo sapiens	81-84	
33082208-8	2021	We demonstrate that increased MET expression in RET fusion-positive tumor cells causes resistance to selpercatinib, and this can be overcome by combining selpercatinib with crizotinib.	Crizotinib	173-183	ret proto-oncogene	Homo sapiens	48-51	
31768065-3	2019	In this study, we uncovered activating mutations in CSF1R and rearrangements in RET and ALK that conferred dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib, respectively, in patients with histiocytosis.	Crizotinib	177-187	ret proto-oncogene	Homo sapiens	80-83	
33324391-1	2020	The drug resistance of first-line crizotinib therapy for ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable.	Crizotinib	34-44	ret proto-oncogene	Homo sapiens	79-103	
31639374-1	2019	Crizotinib is an oral small-molecule tyrosine kinase inhibitor targeting anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) and MET proto-oncogene, receptor tyrosine kinase (MET).	Crizotinib	0-10	ret proto-oncogene	Homo sapiens	129-153	
31639374-1	2019	Crizotinib is an oral small-molecule tyrosine kinase inhibitor targeting anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) and MET proto-oncogene, receptor tyrosine kinase (MET).	Crizotinib	0-10	ret proto-oncogene	Homo sapiens	185-209